Impact of different diagnostic measures on drug class association 1 with dementia progression risk: a longitudinal prospective cohort 2 study 3 Daman Kaur^{a*}, Magda Bucholc^b, David P. Finn^c, Stephen Todd^d, KongFatt 4 Wong-Lin^b, Paula L. McClean^a 5 6 ^a Northern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute, 7 Ulster University, Clinical Translational Research and Innovation Centre (C-TRIC), Altnagelvin Hospital Site, Derry~Londonderry BT47 6SB, Northern Ireland, UK. Ph: +44 (0) 2871675675 8 9 ^b Intelligent Systems Research Centre, School of Computing, Engineering and Intelligent Systems, Ulster University, Northland Rd, Derry~Londonderry BT48 7JL, Northern Ireland, UK. 10 Ph: +44 (0) 2871675320 11 ^c Pharmacology and Therapeutics, School of Medicine, Galway Neuroscience Centre, Human 12 13 Biology Building, National University of Ireland Galway, University Road, Galway H91 W5P7, Republic of Ireland. Ph: +353-91-495586 14 ^d Altnagelvin Area Hospital, Western Health and Social Care Trust, Derry~Londonderry BT47 15 6SB, Northern Ireland, UK. Ph: +44 (0) 2871345171 16 17 *Corresponding author: Daman Kaur, kaur-d1@ulster.ac.uk, Northern Ireland Centre for 18 Stratified Medicine, Biomedical Sciences Research Institute, Ulster University, C-TRIC, 19 Altnagelvin Hospital Site, Derry~Londonderry BT47 6SB, Northern Ireland, UK. 20 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Declarations of interest: none 21

22 Abstract

Background: Clinical Dementia Rating Sum of Boxes (CDRSOB) scale is known to be highly
indicative of cognitive-functional status, but it is unclear whether it is consistent with clinician
diagnosis in evaluating drug class associations with risk of progression to mild cognitive
impairment (MCI) and dementia.

27

28 Methods: We employed multivariate logistic regression on longitudinal NACC data, to identify 29 drug classes associated with disease progression risk, using clinician diagnosis and CDRSOB as 30 the outcome.

31

Results: Non-steroidal anti-inflammatory drugs, anxiolytics, antidiabetics, and Parkinson's 32 medications were significantly associated with decreased progression to mild cognitive 33 34 impairment (MCI)/dementia, and antihypertensives and Alzheimer's medications significantly 35 associated with increased progression risk. Associations were however dependant on the diagnostic measure used, e.g., antihypertensives were associated with increased Healthy-to-36 Dementia risk using clinical diagnosis as the outcome (OR:2.05, FDR p<0.001), but not for 37 CDRSOB. Additionally, some associations appear to be gender specific; for instance, 38 antidiabetics had lower MCI-to-Dementia risk for women (OR:0.58, FDR p=0.006) using 39 40 CDRSOB. Further, in accordance with existing literature, acetylcholinesterase inhibitors were 41 not beneficial in delaying dementia.

43	Conclusions: Overall, we demonstrate that choice of diagnostic measure can influence the
44	magnitude of risk or protection attributed to drug classes. A consensus must be reached
45	within the research community with respect to the most accurate diagnostic outcome to
46	identify risk and improve reproducibility.

47

Funding: This project was supported by the European Union's INTERREG VA Programme, managed by the Special EU Programmes Body (SEUPB (Centre for Personalised Medicine, IVA 50 5036)), with additional support by the Northern Ireland Functional Brain Mapping Project Facility (1303/101154803), funded by invest Northern Ireland and the University of Ulster (K.W.-L.), Alzheimer's Research UK (ARUK) NI Pump Priming (M.B.,S.T.,K.W.-L.,P.L.M.), Ulster University Research Challenge Fund (M.B.,S.T.,K.W.-L.,M.B.), and the Dr George Moore Endowment for Data Science at Ulster University (M.B.).

55

56 Introduction

Dementia is a complex disease with several subtypes and aetiologies, and few effective therapeutics (Arvanitakis et al., 2019). Therefore, extensive research has been carried out analysing factors that may influence disease incidence and progression (Livingston et al., 2020; Peters et al., 2019). Medications, in particular, may affect cognition in older adults (Barton et al., 2008; Nikaido et al., 1990) due to increased drug sensitivity associated with age-related factors such as impaired liver metabolism and decreased renal function (Barton et al., 2008). Moreover, factors like potentially inappropriate prescribing, drug interactions

and polypharmacy, which are common in dementia patients, complicate the assessment of
 specific drug classes on cognition (Delgado et al., 2019).

66 Several pharmacoepidemiology studies have analysed the relationship between medications and dementia risk with conflicting findings. Researchers have acknowledged that 67 methodological differences substantially contribute to the variation in risk attributed to 68 69 different medications. Study design, inclusion criteria, data preparation, and especially the diagnostic criteria used can influence outcomes (Erkinjuntti et al., 1997; Jamsen et al., 2016; 70 71 Wancata et al., 2007). One study examining antidiabetic medications found protective effects of metformin on dementia risk (Chin-Hsiao 2019), whereas another reported increased risk 72 of cognitive impairment associated with metformin use (Moore et al., 2013). For 73 antihypertensives, one systematic review reported a significant association between reduced 74 dementia risk and use of diuretics and angiotensin-converting enzyme (ACE) inhibitors (Shah 75 et al., 2009), whereas a study by Rouch et al. (2015) showed that calcium (Ca²⁺) channel 76 77 blockers and renin-angiotensin system blockers, were associated with prevention of dementia. Similarly, discrepant findings across studies have been reported on the association 78 between anxiolytics, such as benzodiazepines, and cognitive decline (Salzman, 2020; Verdoux 79 et al., 2005). This is also the case for other drug classes including antidepressants, 80 antipsychotics, and non-steroidal anti-inflammatory (NSAIDs) (Biringer et al., 2009; Hill et al., 81 2010; Imbimbo et al., 2010; Zhang et al., 2018). We note significant variability in the diagnostic 82 83 criteria used across studies that undoubtedly impacts upon risk attribution leading to conflicting findings. 84

Clinical assessment of dementia involves detailed examination of medical history, cognitive tests followed by laboratory assays, psychiatric evaluation, and brain imaging to

identify dementia subtype. Studies have shown that subtle differences in classification 87 associated with National Institute of Neurological and Communicative Disorders and Stroke-88 Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA), Diagnostic and 89 Statistical Manual Of Mental Disorders (DSM) criteria including DSM–III–R, DSM–IV, DSM-V, 90 91 International Classification of Diseases (ICD) criteria including ICD-9, ICD-10, ICD-11, and Cambridge Mental Disorders of the Elderly Examination (CAMDEX) criteria can influence 92 93 clinical diagnosis, and lead to variation in dementia prevalence (Berman & Bursztajn 1999; 94 Chaves et al., 2007; Erkinjuntti et al., 1997; Wancata et al., 2007). As a result of this variation, researchers often employ cognitive scores for analysis, especially in longitudinal studies as 95 96 they allow for identifying small changes in cognition over time. However, in clinical settings cognitive tests are mainly used to aid the diagnostic decision-making process. 97

The Clinical Dementia Rating (CDR[®] Dementia Staging Instrument) scale, a cognitive 98 assessment tool, is regularly used in clinical and research settings to gauge dementia severity. 99 100 It provides a global score, and a more detailed CDR sum of boxes (CDRSOB) score obtained 101 through patient and informant interview based on the following cognitive and functional domains; memory, orientation, judgment & problem solving, community affairs, home & 102 hobbies, and personal care (Morris, 1993). Studies have reported moderate (Forsell et al., 103 1992; Juva et al., 1994), to good (Chaves et al., 2007; Ding et al., 2018; Lima et al., 2017) 104 correlation of the CDR scale with DSM and McKhann (1984) diagnostic criteria, with one study 105 106 reporting efficiency of CDRSOB in distinguishing MCI from dementia for patients with CDR global score 0.5 (O'Bryant et al., 2010). However, it is unclear whether such cognitive-107 functional assessments are consistent with clinical diagnosis in terms of evaluating the 108 benefits or risks of medications. 109

In this study, we investigate how the associations between medications and dementia 110 risk vary between clinical diagnosis and CDRSOB scores generally, and differentially in men 111 and women (Trenaman et al., 2009). We analysed several drug classes available in the 112 National Alzheimer's Coordinating Center (NACC) dataset, namely, antihypertensives, lipid 113 lowering medication, NSAIDs, anticoagulants, antidepressants, antipsychotics, anxiolytics, 114 antidiabetics, Alzheimer's disease (AD) medication and Parkinson's disease (PD) medication, 115 and subcategories of drugs within each class, for those significantly associated with 116 117 progression to MCI, all-cause dementia, and AD.

118

119 Results

Using multivariate logistic regression, we identified drug classes associated with risk of 120 121 progression from Healthy-to-MCI, Healthy-to-Dementia, Healthy-to-AD, MCI-to-Dementia, and MCI-to-AD for both CDRSOB and clinical diagnosis as the outcome. The adjusted odds 122 ratios were calculated based on drug exposure vs. absence of the drug of interest during the 123 timeline available within the NACC dataset. The mean conversion time (standard deviation) 124 in years was 5.4 (3.1) for stable healthy, 6.7 (2.9) for Healthy-to-MCI, 3.1 (2.2) for stable MCI, 125 7 (2.6) for Healthy-to-Dementia, and 5.5 (2.3) for MCI-to-Dementia progression group. For 126 brevity, significant results are illustrated in Figures 1-4. Complete results, including 127 insignificant associations, can be found in Supplementary Table 1. 128

129

130

132 NSAIDs reduce Healthy-to-MCI progression risk with clinical diagnosis as the outcome

Progression analysis comparing stable healthy individuals to those who progressed 133 134 from Healthy-to-MCI, revealed antihypertensives and AD medications were significantly associated with increased progression risk with both CDRSOB and clinical diagnosis as the 135 diagnostic measure (FDR p<0.001). NSAIDs, on the other hand, significantly reduced 136 137 progression risk only with clinical diagnosis (FDR p<0.001; Fig. 1A). For women specifically, antihypertensives were significantly associated with increased progression risk for both 138 CDRSOB and clinical diagnosis (FDR p<0.001), whereas AD medications were significantly 139 associated with progression risk only for clinical diagnosis as the outcome for women 140 specifically (FDR p<0.001; Fig. 1A). 141

142

Antihypertensives increase Healthy-to-Dementia risk overall, and in women with clinical diagnosis as the outcome

In terms of Healthy-to-Dementia progression, AD medications were significantly associated with increased progression risk overall, and for both women and men separately, for both CDRSOB and clinical diagnosis (FDR p<0.001; Fig. 1B). Antihypertensives were significantly associated with increased progression risk overall and specifically for women only with clinical diagnosis as the outcome (FDR p<0.001; Fig. 1B).


150

151


Anxiolytics and antidiabetics reduce MCI-to-Dementia progression risk with CDRSOB as the outcome

155	Comparing stable MCI individuals to those who progressed from MCI-to-Dementia, AD
156	medications were significantly associated with increased progression risk overall, and in men
157	and women separately, with clinical diagnosis and CDRSOB (FDR p<0.001; Fig. 1C). Anxiolytics
158	were significantly associated with reduced progression risk overall with CDRSOB score.
159	Similarly, diabetes medications were associated with reduced MCI-to-Dementia risk overall
160	(FDR p<0.001) and specifically for women (FDR p<0.01) with CDRSOB as the outcome (Fig. 1C).
161	
162	
163	
164	
165	
166	
167	

perpetuity. All rights reserved. No reuse allowed without permission.



168






Fig. 1: Summary grouped forest plots of adjusted odds ratios for drug classes significantly associated with risk of progression to MCI and dementia for two diagnostic variables; clinical diagnosis and CDRSOB scores. Progression groups analysed: (A) Remained Healthy vs. Healthy-to-MCI; (B) Remained Healthy vs. Healthy-to-Dementia; (C) Remained MCI vs. MCI-to-Dementia. (AD: Alzheimer's Disease; NSAIDs: Non-steroidal anti-inflammatory drugs; CDRSOB: Clinical Dementia Rating sum of boxes).

187 Antihypertensives increase Healthy-to-AD risk with clinical diagnosis as the outcome

Next, we compared stable healthy individuals with those who progressed from Healthy-to-AD (Fig. 2A). The results obtained were analogous to the analysis focusing on allcause dementia in terms of OR values and significance. Antihypertensives were significantly associated with increased progression risk overall and specifically for women with clinical diagnosis as the outcome (FDR p<0.001; Fig. 2A). AD medications were significantly associated with increased progression risk overall, and for both women and men separately, for both CDRSOB and clinical diagnosis (FDR p<0.001; Fig. 2A).


195

196 Anxiolytics in women and Parkinson's medication in men are associated with reduced MCI-


197 to-AD progression risk

Analysis comparing stable MCI individuals with those who progress from MCI-to-AD 198 199 revealed that anxiolytics significantly reduced progression risk with clinical diagnosis (FDR p<0.01) and CDRSOB (FDR p<0.001) as the outcome (Fig. 2B). Whereas for women, anxiolytics 200 reduced progression risk only with CDRSOB as the outcome (FDR p<0.01). AD medication was 201 associated with increased risk for both diagnostic variables overall, and for both women and 202 men, whereas Parkinson's medications significantly reduced progression risk overall, and 203 204 specifically for males with clinical diagnosis (FDR p<0.01) and CDRSOB (FDR p<<0.001) as the 205 outcome (Fig. 2B).

All rights reserved. No reuse allowed without permission.



207



208

Fig. 2: Summary grouped forest plots of adjusted odds ratios for drug classes significantly associated with risk of progression to AD for two diagnostic variables; clinical diagnosis and CDRSOB scores. Progression groups analysed: (A) Remained Healthy vs. Healthy-to-AD; (B) Remained MCI vs. MCI-to-AD. (AD: Alzheimer's Disease; PD: Parkinson's Disease; CDRSOB: Clinical Dementia Rating sum of boxes).

215 Propionic acid derivatives reduce healthy to MCI and dementia progression risk

216	We then focused on subcategories, or drug classes, of the significant drug families obtained
217	from primary analyses. In terms of NSAIDs, propionic acid derivatives were significantly
218	associated with reduced Healthy-to-MCI progression risk in general (FDR p<0.001) and
219	specifically for women (FDR p<0.01) with CDRSOB score (Fig. 3A). With clinical diagnosis as
220	the outcome, propionic acid derivatives were associated with significantly reduced Healthy-
221	to-Dementia progression risk overall (FDR p<0.001) and specifically in females (FDR p<0.01;
222	Fig. 3A). Propionic acid derivatives were also associated with significantly reduced Healthy-
223	to-AD progression risk (FDR p<0.01; Fig. 3C) with clinical diagnosis, but not CDRSOB.


Moving on to antihypertensives, diuretics were significantly associated with increased Healthy-to-MCI progression risk in women with CDRSOB as the outcome (FDR p<0.01; Fig. 3A). With CDRSOB as the diagnostic outcome, antiadrenergic agents were associated with significantly reduced MCI-to-Dementia risk in men (FDR p<0.001; Fig. 3B), and more specifically with reduced MCI-to-AD progression risk in men (FDR p<0.01; Fig. 3C).

229


Benzodiazepines and sulfonylureas are associated with reduced MCI-to-Dementia risk with CDRSOB as outcome

With respect to anxiolytics, benzodiazepines were associated with significantly reduced MCI-to-Dementia progression risk with CDRSOB (FDR p<0.01; Fig. 3B), but not clinician diagnosis. Furthermore, benzodiazepines were associated with reduced MCI-to-AD progression risk in general (FDR p<0.001) and specifically for both men and women (FDR p<0.01) with CDRSOB (Fig. 3C).

237	With CDRSOB as the diagnostic measure, the sulfonylurea class of antidiabetic drugs
238	was significantly associated with reduced MCI-to-Dementia risk (FDR p<0.01; Fig. 3B).
239	Furthermore, dopamine precursors, a class of Parkinson's disease medication, were
240	associated with significantly reduced MCI-to-AD progression risk (FDR p<0.001; Fig. 3C) only
241	with CDRSOB as the diagnostic outcome.
242	
243	
244	
245	
246	
247	
248	
249	



251






Fig. 3: Summary grouped forest plots of adjusted odds ratios of specific drug classes significantly associated with risk of progression to MCI, dementia, and AD for two diagnostic variables; clinical diagnosis and CDRSOB scores. Progression groups analysed: (A) Remained Healthy vs. Healthy-to-MCI, Remained Healthy vs. Healthy-to-Dementia; (B) Remained MCI vs. MCI-to-Dementia; (C) Remained Healthy vs. Healthy-to-AD and Remained MCI vs. MCI-to-AD.

AD drug treatments in individuals with MCI are associated with increased risk of dementia and AD


271 Commonly prescribed AD medications were analysed in participants who remained MCI over time vs. those who progressed from MCI to AD specifically or dementia in general. 272 Donepezil, a cholinesterase inhibitor (ChEI) was significantly associated with increased MCI-273 274 to-Dementia risk (FDR p<0.001; Fig. 4A) and MCI-to-AD risk (FDR p<0.001; Fig. 4B) in general, and in men and women with both clinical diagnosis and CDRSOB as the outcome. Memantine, 275 an N-methyl-D-aspartate (NMDA) receptor antagonist was also significantly associated with 276 277 increased MCI-to-Dementia and MCI-to-AD risk overall and specifically for women with CDRSOB (FDR p<0.001; Fig. 4), but not clinical diagnosis. 278

Another ChEI, Galantamine, was associated with increased MCI-to-Dementia risk in 279 general (FDR p<0.001) and specifically for men (FDR p<0.001; Fig.4A), and increased MCI-to-280 AD progression risk (FDR p<0.001; Fig.4B) with CDRSOB as the diagnostic measure, but not 281 clinical diagnosis. Rivastigmine was significantly associated with increased MCI-to-Dementia 282 283 risk overall (FDR p<0.001) and specifically for men (FDR p<0.01; Fig.4A) with CDRSOB as the diagnostic measure. In terms of MCI-to-AD progression, rivastigmine was significantly 284 associated with increased risk of progression overall (FDR p<0.001), and in both women and 285 men (FDR p<0.01 & FDR p<0.001 respectively) with CDRSOB as the outcome, but not clinical 286 diagnosis (Fig.4B). 287

288 Combined prescription of memantine and donepezil was significantly associated with 289 increased MCI-to-Dementia (FDR p<0.001; Fig. 4A) and MCI-to-AD risk (FDR p<0.001; Fig. 4B) 290 in general, and specifically in women and men with both CDRSOB and clinical diagnosis.

All rights reserved. No reuse allowed without permission.

Remained MCI vs. MCI-to-De	mentia		Clinical Diagnosis CDRSOB Odds Ratio (95% Cl) FDR p Odds Ratio (95% Cl)	FDR p
			Remained MCI (n=1895) vs. Remained MCI (n=379 MCI-to-Dementia (n=1041) MCI-to-Dementia (n=1	
Donepezil			1.71 (1.44-2.03) <0.001 2.10 (1.85-2.38)	<0.00
Memantine			1.61 (1.14-2.28) 0.02 1.89 (1.53-2.33)	<0.0
Galantamine			1.72 (1.16-2.53) 0.02 2.26 (1.73-2.95)	<0.0
Rivastigmine			1.34 (0.93-1.93) 0.34 1.62 (1.28-2.05)	<0.0
Memantine + Donepezil			2.47 (1.89-3.21) <0.001 2.45 (2.09-2.88)	<0.0
			Remained MCI (n=918) vs. MCI-to-Dementia (n=485) Remained MCI (n=184 vs. MCI-to-Dementia (
nen: Donepezil			1.68 (1.30-2.19) <0.001 2.16 (1.80-2.60)	<0.0
Memantine			2.19 (1.29-3.69) 0.02 2.63 (1.92-3.60)	<0.0
Memantine + Donepezil			2.42 (1.62-3.61) <0.001 2.52 (1.98-3.21)	<0.0
			Remained MCI (n=977) Remained MCI (n=195 vs. MCI-to-Dementia (n=556) vs. MCI-to-Dementia ('
n: Donepezil		•	1.71 (1.36-2.15) <0.001	<0.0
Galantamine		• • •	1.76 (1.07-2.92) 0.08 2.81 (1.98-3.99)	<0.0
Rivastigmine		• <u> </u>	1.79 (1.12-2.85) 0.06 1.63 (1.19-2.23)	<0.0
Memantine + Donepezil			2.51 (1.76-3.57) <0.001 2.42 (1.95-3.00)	<0.0
			50 C-02	



291

Fig. 4: Summary grouped forest plots of adjusted odds ratios for AD drugs significantly associated with risk of progression to dementia and AD for two diagnostic variables; clinical diagnosis and CDRSOB scores. Progression groups analysed: (A) Remained MCI vs. MCI-to-Dementia; (B) Remained MCI vs.

295 MCI-to-AD. (CDRSOB: Clinical Dementia Rating sum of boxes).

296

297 Discussion

In this study, we demonstrate that the use of different diagnostic measures for MCI and 298 dementia, i.e., clinical diagnosis and CDRSOB scores, affect the magnitude of the association 299 300 of various medications with disease risk and progression. From the drug classes analysed, antihypertensives, NSAIDs, anxiolytics, antidiabetics, AD and PD medications were found to 301 be differentially associated with risk of progression to MCI, all-cause dementia, and AD with 302 respect to the diagnostic measure used. Additionally, subcategories of these drug classes; 303 antiadrenergics, ACE inhibitors, propionic acid derivatives, benzodiazepines, sulfonylureas, 304 and dopamine precursors were associated with decreased risk of progression, and diuretics 305 306 were associated with increased progression risk.

307 In the NACC dataset, consensus-based clinical diagnosis was made using the criteria proposed by McKhann et al. (Mckhann et al., 1984; Mckhann et al., 2011). A previous study, 308 309 analysing the NACC dataset, reported diagnostic accuracy with 0.71 sensitivity and 0.81 specificity when comparing CDRSOB scores to dementia diagnosis (O'Bryant et al., 2010). We 310 311 report that despite good correlation between the two diagnostic measures, our analysis produced discordant results while analysing risk associated with different medications. With 312 313 the exception of AD and PD medications, whilst odds ratios were consistently in the same direction, the statistical significance of results was inconsistent for the two diagnostic 314 315 measures.

The CDRSOB scale offers a wider score range allowing better demarcation of subtle changes between different stages of disease progression. In the NACC cohort (Fig. 1-3), a lower number of individuals are classified into Healthy-to-MCI group by clinical diagnosis

(n=438), compared to CDRSOB score (n=646). This suggests that CDRSOB scale can detect early disease symptoms and help diagnose MCI. Whereas in terms of a clinical diagnosis, there are no specific tests that confirm MCI, judgement is made based on clinical evaluation and exclusion of other causative factors such as hypothyroidism or vitamin B12 deficiency. These factors not only affect the prevalence of MCI and dementia in a cohort but may also lead to variation in risk analysis.

In our study, PD medications were associated with reduced MCI-to-AD risk overall, and specifically for men with both diagnostic measures, given that PD is more common in males. Dopamine precursors, in particular, were associated with significantly reduced MCI-to-AD risk with CDRSOB as the outcome. Studies have shown that levodopa treatment can have beneficial effect on cognition (Ikeda et al., 2017). Additionally, PD related MCI is clinically distinct and has a longer conversion period to dementia, compared to AD related MCI (Besser et al., 2016).

While focusing on specific AD drugs for MCI-to-Dementia and MCI-to-AD progression, 332 333 donepezil, and a combination of donepezil and memantine, were significantly associated with 334 increased risk of disease progression with both clinical diagnosis and CDRSOB as the outcome. However, memantine, galantamine, and rivastigmine were found to be significantly 335 associated only with CDRSOB as the outcome. Previous studies have shown faster cognitive 336 decline with ChEI therapy in MCI and early AD (Han et al., 2019; Schneider et al., 2011). These 337 associations could be due to confounding by indication since patients with cognitive 338 339 impairment are more likely to be prescribed these drugs. It also reflects the prescribing patterns across clinics since, in contradiction to the US FDA guidelines, physicians are known 340 to prescribe ChEIs and memantine during early stages of impairment (Schneider et al., 2011). 341

Additionally, we found significant MCI-to-Dementia risk associated with memantine in women, and galantamine and rivastigmine in men.

344 Antihypertensives were significantly associated with increased Healthy-to-MCI risk overall, and specifically for women, for both clinical diagnosis and CDRSOB diagnostic 345 measures. However, for Healthy-to-Dementia/AD progression, antihypertensives were 346 347 associated with significantly increased progression risk only with clinical diagnosis as the outcome. Several studies have reported increased risk of cognitive impairment associated 348 with hypertension, and a subsequent reduced risk with antihypertensive treatment. 349 However, there still exists ambiguity regarding the duration, specific drug subclass and 350 optimal dosage to prevent cognitive impairment (Ou et al., 2020). A previous study analysing 351 the NACC dataset reported an increased AD risk with intensive treatment for systolic BP, 352 especially in those with comorbid depression (Yeung et al., 2019); another found lower 353 cognitive scores associated with lower systolic BP (Fiford et al., 2020). Furthermore, with 354 355 CDRSOB as the outcome, diuretics were associated with increased Healthy-to-MCI risk for women specifically, and antiadrenergics reduced MCI-to-Dementia/AD risk for men. Although 356 studies have shown reduced risk of AD/dementia with diuretic therapy (DeLoach & Beall, 357 358 2018; Yasar et al., 2013), our analysis reports an increased risk of cognitive impairment in 359 women.

With respect to NSAIDs, conflicting outcomes have been reported in observational and experimental studies (Ali et al., 2019; Breitner et al., 2009; Cote et al., 2012). Our analysis showed reduced Healthy-to-MCI risk with clinical diagnosis. However, in terms of subcategories, propionic acid derivatives were associated with reduced Healthy-to-MCI risk with CDRSOB, and reduced Healthy-to-Dementia/AD risk with clinical diagnosis. Commonly

used propionic acid derivatives, such as ibuprofen and naproxen, have been associated with
delayed or decreased rate of cognitive decline (Grodstein et al., 2008; Leoutsakos et al., 2011).
NSAID use may also lead to modulation of inflammatory pathways which can be beneficial as
inflammatory genes and molecules have been linked with AD development (Newcombe et al.,
2018; Raj et al., 2017). Additionally, studies have shown that some NSAIDs can mediate Aβ
clearance. However, it is only effective during the early disease stages (Imbimbo et al., 2010).

In the case of anxiolytics, results were consistent for both clinical diagnosis and 371 CDRSOB with a reduced MCI-to-Dementia and MCI-to-AD progression risk. However, while 372 373 analysing subcategories, we found benzodiazepines to be associated with reduced MCI-to-Dementia and MCI-to-AD progression risk only with CDRSOB as the outcome. Anxiety and 374 related disorders are speculated to be symptoms and risk factors of dementia (Gimson et al., 375 2017). Several studies have reported an increased dementia risk with anxiolytics. However, a 376 previous study, analysing NACC data, demonstrated neutralised disease progression risk in 377 378 MCI and AD patients suffering from anxiety, and apolipoprotein E4 carriers who were prescribed certain anxiolytics (Burke et al., 2017). 379

We found antidiabetics were significantly associated with reduced MCI-to-Dementia 380 risk, and specifically for women with CDRSOB as the outcome. Despite the association of 381 diabetes with lower cognitive function, several studies have reported a reduced dementia risk 382 in those taking oral hypoglycaemic medication (Hsu et al., 2011; Kim et al., 2019; Wu et al., 383 2020). Further analysis of drug subcategories in the present study revealed reduced MCI-to-384 385 Dementia risk with CDRSOB associated with sulfonylureas. Again, there are inconsistent results in the literature regarding sulfonylureas and associated dementia risk. Some have 386 reported an increased risk which might be linked to intensive treatment leading to 387

hypoglycaemia (Zammitt & Frier, 2005). Using CDRSOB as the outcome, studies have shown
that glycaemic trajectories, can predict cognitive performance (Springer et al., 2014).

390 Overall, our study shows that the magnitude and significance of association of different medications with disease progression can vary depending on the diagnostic measure 391 used. CDRSOB scores, though comparatively less comprehensive, form a part of clinical 392 393 diagnosis which leads to high correlation between the two. Due to unavailability of clinical diagnosis in some datasets, or a preference for quantitative analysis to increase precision and 394 reduce subjectivity, researchers often opt for cognitive scores. However, we must be aware 395 396 of the implications of choosing a particular diagnostic measure, and careful regarding how we interpret the results. 397

There were limitations in this study, such as the low number of individuals while 398 analysing subcategories of drug classes. Importantly, it should be noted that significant results 399 obtained in this study are associations and not causation, as the data was not generated from 400 randomised controlled trials. Therefore, our findings are vulnerable to unmeasured 401 402 confounders or confounding by indication, with AD drugs for example. Surprisingly, it was 403 observed that some cognitively healthy individuals (clinical diagnosis, n=108; CDRSOB, n=63) were taking AD medication, either a reflection of genuine prescribing patterns for AD drugs 404 or errors at the point of data entry. Moreover, in this study exposure to the drug classes was 405 analysed irrespective of duration, dosage, and drug-drug interactions. There is a need for 406 407 more detailed analyses on larger cohorts, including real-world clinical databases, for further 408 evaluation to identify the most relevant diagnostic measure and to inform prescribing patterns in order to reduce modifiable risk of dementia. Additionally, based on our results we 409 believe that further studies should focus on a gender stratified approach as there may be 410

differential risk profiles associated with various subcategories of drug classes in men andwomen.

413

414 Materials and Methods

415 Data source

Archival data from the National Alzheimer's Coordinating Center (NACC), consisting of over 500 variables on genetic, lifestyle and clinical features for 34,848 individuals was used in this study. Details about the NACC, recruitment of participants, and assessment process has been previously described (Besser et al., 2018; Morris et al., 2006).

The NACC Uniform Data Set (UDS), comprising of data collected from September 2005 420 until June 2018 was used in our analysis. Written, informed consent from all participants and 421 co-participants included in NACC-UDS was obtained by the Alzheimer's disease research 422 centers (ADRCs) where they completed their study visits. The following drug classes were 423 424 analysed: antihypertensives, lipid lowering medication, NSAIDs, anticoagulants/antiplatelets, antidepressants, antipsychotic agents, anxiolytics/sedatives/hypnotics, diabetes medication, 425 AD medication, and Parkinson's disease medication. The diagnostic category of participants 426 was determined based on both clinical diagnosis and CDRSOB scores. In NACC-UDS Version 1 427 and 2, the process of clinical diagnosis for all-cause dementia relied on the diagnostic protocol 428 429 of the ADRC, with centres generally using DSM-IV (1994) or NINCDS-ADRDA guidelines. In 430 NACC-UDS Version 3, the criteria for all-cause dementia was modified from McKhann (2011). Diagnoses of MCI were established using the modified Petersen criteria. Individuals included 431 in the analyses were aged \geq 40 years. 432

433

	Diagnostic criteria for UDS version 1.0 – 2.0	Diagnostic criteria for UDS version 3.0
Mild cognitive impairment (MCI)	Petersen & Morris, 2005	Petersen & Morris, 2005
Alzheimer's	NINCDS-ADRDA criteria (McKhann	NIA-AA criteria
disease (AD)	et al., 1984)	(McKhann et al., 2011)
All-cause dementia	Not specified (McKhann et al., 1984 or DSM-IV)	McKhann et al., 2011

434

435 Data preparation


436 A multi-time-point data preparation approach was employed to conduct progression analysis. Clinical diagnosis and CDRSOB scores were identified across all visits for each participant to 437 determine changes in cognitive status over time. Subsequently, five comparisons were 438 439 assessed for both diagnostic measures (Table 1) for the following six progression groups; participants that were healthy across all visits (Remained Healthy), participants that were MCI 440 441 across all visits (Remained MCI), those who progressed from Healthy-to-MCI, from Healthyto-AD, from MCI-to-Dementia, and from MCI-to-AD. CDRSOB scores were categorized as 442 443 healthy: 0, MCI: 0.5-4.0 and dementia: 4.5-18 (O'Bryant et al., 2010). Details about the data cleaning procedure have been published previously (Kaur et al., 2020). 444

445

Table 1: Progression groups analysed using multivariate logistic regression.

Clinical Diagnosis	CDRSOB score	448
Remained Healthy (7870) vs.	Remained Healthy (6999) vs.	449
Healthy-to-MCI (706)	Healthy-to-MCI (1034)	
Remained Healthy (7870) vs.	Remained Healthy (6999) vs.	450
Healthy-to-Dementia (506)	Healthy-to-Dementia (359)	451
Remained MCI (1895) vs.	Remained MCI (3796) vs.	
MCI-to-Dementia (1041)	MCI-to-Dementia (1766)	452
Remained Healthy (7870) vs.	Remained Healthy (6999) vs.	
Healthy-to-AD (382)	Healthy-to-AD (270)	453
Remained MCI (1895) vs.	Remained MCI (3796) vs.	454
MCI-to-AD (826)	MCI-to-AD (1422)	454

455



457

3 4	Antihypertensives	NSAIDs	Anxiolytics	Diabetes medication	AD medication	Parkinson's medication
	Antihypertensive	Selective	Barbiturates	Sulfonylureas	Memantine+	Dopamine
1	combination therapy	COX-2 inhibitors			Donepezil combination	precursor
4	ACE inhibitors Antiadrenergic agents	Propionic acid derivatives	Benzodiazepines	Thiazolidinediones combination drugs	Donepezil	Dopamine receptor agonist
				Alpha-glucosidase		
E	Beta blocker	Enolic acid	Sedatives/	inhibitors	Memantine	COMT
	Calcium channel blocker	derivatives	Hypnotics			inhibitors
				SGLT-2 inhibitors		
	Angiotensin II Inhibitor	Acetic acid derivatives	Antihistamines		Galantamine	MAO-B inhibitors
				Insulin		
1	Diuretic	Salicylates	Azapirones		Rivastigmine	Anticholinergic
,	Vasodilator			DPP-4 inhibitors	Tacrine	
				Biguanides		
				Incretin mimetics		
				Meglitinides		

458

Fig. 5: (A) Drug classes available in the NACC UDS analysed in the present study. Statistically significant 459 460 classes (shaded green; FDR p <0.01) obtained from multivariate logistic regression. (B) Based on their mechanism of action, subcategories of significant drug classes were further analysed. (NACC: National 461 462 Alzheimer's Coordinating Center; NSAIDs: Nonsteroidal anti-inflammatory drugs; AD: Alzheimer's 463 Disease; ACE: Angiotensin-converting enzyme; COX-2: Cyclooxygenase-2; SGLT-2: Sodium-glucose co-464 transporter-2; DPP-4: Dipeptidyl peptidase-4; COMT: Catechol-O-methyltransferase; MAO-B: 465 Monoamine oxidase type B).

466

467	The major drug classes analysed in this study, and subcategories of antihypertensives are
468	available in the UDS dataset as variables. For subcategorising the other significant drug classes
469	(Fig. 5), we used the researcher's data dictionary (RDD) to identify the common drug names
470	stored in the UDS. Next, we searched for specific drug terms (Supplementary Table 2) across
471	all visits to determine prescription data for each individual, those who reported a specific drug
472	at least during one visit were classified as taking the medication. These were then categorised
473	based on their mechanism of action (Fig. 5B). Medications with ophthalmic and topical routes
474	of administration were excluded from this analysis.

475

476 Statistical analysis

In order to explore the associations between different drug classes and disease progression, 477 multivariate logistic regression was employed which controls for confounders (Glonek et al., 478 479 1995). Drug classes illustrated in Fig. 5A, were first analysed together, followed by analysing subcategories of respective significant drug classes (as depicted column wise in Fig. 5B). 480 481 Additionally, the analysis was repeated for men and women separately, to determine sex-482 specific effects associated with drug exposure. Adjustment for multiple hypothesis testing was achieved by applying false discovery rate (FDR) using the Benjamini-Yekutieli correction 483 method (Benjamini & Yekutieli, 2001). FDR adjusted p-values (FDR p) <0.01 were considered 484 statistically significant. 485

486

488 Software and codes

489	Statistical analyses were performed using the 'PredictABEL' package in R studio (Version
490	1.1.423) on a Windows machine with eight memory cores. Codes will be uploaded to GitHub.
491	
492	
493	
494	
495	
496	
497	
498	
499	
500	
501	
502	
503	
504	
505	
506	

507 Acknowledgements

508	1. This project was supported by the European Union's INTERREG VA Programme, managed
509	by the Special EU Programmes Body (SEUPB (Centre for Personalised Medicine, IVA 5036)),
510	with additional support by the Northern Ireland Functional Brain Mapping Project Facility
511	(1303/101154803), funded by invest Northern Ireland and the University of Ulster (K.WL.),
512	Alzheimer's Research UK (ARUK) NI Pump Priming (M.B.,S.T.,K.WL.,P.L.M.), Ulster University
513	Research Challenge Fund (M.B.,S.T.,K.WL.,M.B.), and the Dr George Moore Endowment for
514	Data Science at Ulster University (M.B.). The views and opinions expressed in this paper do
515	not necessarily reflect those of the European Commission or the SEUPB.
516	2. The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed
517	by the NIA-funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall,
518	MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50
519	AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146
520	(PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI
521	Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas
522	Wisniewski, MD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey
523	Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD,
524	MS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50
525	AG005131 (PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982
526	(PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30AG053760 (PI Henry
527	Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar
528	Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD),
529	P30 AG049638 (PI Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P50

530	AG033514 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), P50 AG047270
531	(PI Stephen Strittmatter, MD, PhD)."
532	
533	
534	
535	
536	
537	
538	
539	
540	
541	
542	
543	
544	
545	
546	
547	
548	

549 References

568

- Ali, M.M., Ghouri, R.G., Ans, A.H., Akbar, A. & Toheed, A. 2019, "Recommendations for Anti-
- 551 inflammatory Treatments in Alzheimer's Disease: A Comprehensive Review of the Literature",
- 552 Cureus, vol. 11, no. 5, pp. e4620.
- 553 American Psychiatric Association.1994, "Diagnostic and statistical manual of mental 554 disorders: DSM-IV" Washington, pp.866.
- Arvanitakis, Z., Shah, R.C., Bennett, D.A. 2019, "Diagnosis and Management of Dementia:
- 556 Review", JAMA, vol. 322, no. 16, pp. 1589-1599.
- 557 Barton C., Sklenicka J., Sayegh P. & Yaffe, K. 2008, "Contraindicated medication use among
- patients in a memory disorders clinic.", American Journal Geriatric Pharmacotherapy, vol. 6,
 no. 3, pp. 147-152.
- 560 Benjamini, Y. & Yekutieli, D. 2001, "The Control of the False Discovery Rate in Multiple Testing
- under Dependency", The Annals of Statistics, vol. 29, no. 4, pp. 1165-1188.
- 562 Berman, S., Bursztajn, H.J. 1999, "Clinical criteria for three types of dementia had low 563 sensitivity and high specificity." Evidence-Based Mental Health, vol. 2, pp. 91.
- 564 Besser, L., Kukull, W., Knopman, D.S., Chui, H., Galasko, D., Weintraub, S., Jicha, G., Carlsson,
- 565 C., Burns, J., Quinn, J., Sweet, R.A., Rascovsky, K., Teylan, M., Beekly, D., Thomas, G.,
- Bollenbeck, M., Monsell, S., Mock, C., Zhou, X.H., Thomas, N., Robichaud, E., Dean, M.,
- 567 Hubbard, J., Jacka, M., Schwabe-Fry, K., Wu, J., Phelps, C., Morris, J.C. & Neuropsychology

Work Group, Directors, and Clinical Core leaders of the National Institute on Aging-funded US

Alzheimer's Disease Centers 2018, "Version 3 of the National Alzheimer's Coordinating

- 570 Center's Uniform Data Set", Alzheimer Disease & Associated Disorders, vol. 32, no. 4, pp. 351571 358.
- 572 Besser L.M., Litvan I., Monsell S.E., Mock C., Weintraub S., Zhou X.H. & Kukull, W. 2016, "Mild
- 573 cognitive impairment in Parkinson's disease versus Alzheimer's disease.", Parkinsonism and
- 574 Related Disorders, vol. 27, pp. 54-60.
- 575 Biringer, E., Rongve, A. & Lund, A. 2009, "A Review of Modern Antidepressants' Effects on
- 576 Neurocognitive Function", Current Psychiatry Reviews, vol. 5, no. 3, pp. 164-174.
- 577 Burke, S.L., O'Driscoll, J., Alcide, A. & Li, T. "Moderating risk of Alzheimer's disease through
- the use of anxiolytic agents", International journal of geriatric psychiatry, vol. 32, no. 12 pp.
- **579 1312-1321**.
- 580 Breitner, J.C.S., Haneuse, S.J.P.A., Walker, R., Dublin, S., Crane, P.K., Gray, S.L. & Larson, E.B.
- 581 2009, "Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based
- 582 cohort SYMBOL SYMBOL", Neurology, vol. 72, no. 22, pp. 1899-1905.
- 583 Chin-Hsiao, T. 2019, "Metformin and the Risk of Dementia in Type 2 Diabetes Patients.", Aging
- 584 & Disease, vol. 10, no. 1, pp. 37-48.
- Chaves, M.L.F., Camozzato, A.L., Godinho, C., Kochhann, R., Schuh, A., de Almeida, V.L. &
 Kaye, J. 2007, "Validity of the clinical dementia rating scale for the detection and staging of
 dementia in Brazilian patients.", Alzheimer Disease & Associated Disorders, vol. 21, no. 3, pp.
 210-217.
- Cote S., Carmichael P.H., Verreault R., Lindsay J., Lefebvre J. & Laurin, D. 2012, "Nonsteroidal
 anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease.",
 Alzheimer's and Dementia, vol. 8, no. 3, pp. 219-226.

- 592 Delgado, J., Bowman, K. & Clare, L. 2020, "Potentially inappropriate prescribing in dementia:
- a state-of-the-art review since 2007", BMJ Open, vol. 10, no. 1, pp. e029172.
- 594 DeLoach, T. & Beall, J. 2018, "Diuretics: A possible keystone in upholding cognitive health.",
- 595 The Mental Health Clinician, vol. 8, no. 1, pp. 33-40.
- 596 Ding, X., Bucholc, M., Wang, H., Glass, D.H., Wang, H., Clarke, D.H., Bjourson, A.J., Dowey,
- 597 L.R.C., O'Kane, M., Prasad, G., Maguire, L. & Wong-Lin, K. 2018, "A hybrid computational
- ⁵⁹⁸ approach for efficient Alzheimer's disease classification based on heterogeneous data.",
- 599 Scientific Reports, vol. 8, no. 1, pp. 9774.
- Erkinjuntti, T., Ostbye, T., Steenhuis, R. & Hachinski, V. 1997, "The effect of different
 diagnostic criteria on the prevalence of dementia.", New England Journal of Medicine, vol.
 337, no. 23, pp. 1667-1674.
- ⁶⁰³ Fiford C.M., Nicholas J.M., Biessels G.J., Lane C.A., Cardoso M.J. & Barnes, J. 2020, "High blood
- 604 pressure predicts hippocampal atrophy rate in cognitively impaired elders.", Alzheimer's and
- 605 Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 12, no. 1) (pagination, pp. Arte
- 606 Number: e12035. ate of Pubaton: 2020.
- Fink, H.A., Jutkowitz, E., McCarten, J.R., Hemmy, L.S., Butler, M., Davila, H.M.P.A., Ratner, E.,
 Calvert, C., Barclay, T.R., Brasure, M.M.S.P.H., M.L.I.S., Nelson, V.A. & Kane, R.L. 2018,
 "Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and
 Clinical Alzheimer-Type Dementia: A Systematic Review", Annals of Internal Medicine, vol.
 168, no. 1, pp. 39-51.

612	Gallacher, J., Elwood, P., Pickering, J., Bayer, A., Fish, M. & BenShlomo, Y. 2012,
613	"Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study
614	(CaPS)", Journal of Epidemiology & Community Health, vol. 66, no. 10, pp. 869-873.
615	Gimson A., Schlosser M., Huntley J.D. & Marchant, N.L. 2018, "Support for midlife anxiety
616	diagnosis as an independent risk factor for dementia: A systematic review.", BMJ Open, vol.
617	8, no. 4, pp. e019399.
618	Glonek, G.F.V., McCullagh, P. 1995, "Multivariate Logistic Models." Journal of the Royal
619	Statistical Society, vol. 57, pp. 533-546.
620	Grodstein F., Skarupski K.A., Bienias J.L., Wilson R.S., Bennett D.A. & Evans, D.A. 2008, "Anti-

inflammatory agents and cognitive decline in a bi-racial population.", Neuroepidemiology,vol. 30, no. 1, pp. 45-50.

- Han, J., Besser, L.M.M.S.P.H., Xiong, C., Kukull, W.A. & Morris, J.C. 2019, "Cholinesterase
 Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease
 Dementia", Alzheimer Disease & Associated Disorders, vol. 33, no. 2, pp. 87-94.
- Hill, K.S., Bishop, J.R., Palumbo, D. & Sweeney, J.A. 2010, "Effect of second-generation
 antipsychotics on cognition: current issues and future challenges", Expert Review of
 Neurotherapeutics, vol. 10, no. 1, pp. 43-57.

Hsu, C., Wahlqvist, M.L., Lee, M. & Tsai, H. 2011, "Incidence of dementia is increased in type
2 diabetes and reduced by the use of sulfonylureas and metformin.", Journal of Alzheimer's
Disease, vol. 24, no. 3, pp. 485-493.

Ikeda M., Kataoka H. & Ueno, S. 2017, "Can levodopa prevent cognitive decline in patients
with Parkinson's disease?.", American Journal of Neurodegenerative Diseases, vol. 6, no. 2,
pp. 9-14.

635 Imbimbo, B. P., Solfrizzi, V., & Panza, F. 2010, "Are NSAIDs useful to treat Alzheimer's disease

or mild cognitive impairment?." Frontiers in aging neuroscience, vol. 2, pp. 19.

Jamsen, K.M.P.D., Ilomaki, J.P.D., Hilmer, S.N.P.D., Jokanovic, N.B.P., Tan, E.C.K.P.D. & Bell,

638 S.J.P.D. 2016, "A systematic review of the statistical methods in prospective cohort studies

639 investigating the effect of medications on cognition in older people", Research In Social &

- 640 Administrative Pharmacy, vol. 12, no. 1, pp. 20-28.
- Kaur, D., Bucholc, M., Finn, D.P., Todd, S., Wong-Lin, K. & McClean, P.L. 2020, "Multi-timepoint data preparation robustly reveals MCI and dementia risk factors.", Alzheimer's &
 Dementia : Diagnosis, Assessment & Disease Monitoring, vol. 12, no. 1, pp. e12116.
- Kim, J.Y., Ku, Y.S., Kim, H.J., Trinh, N.T., Kim, W., Jeong, B., Heo, T.Y., Lee, M.K. & Lee, K.E.
 2019, "Oral diabetes medication and risk of dementia in elderly patients with type 2
 diabetes.", Diabetes Research & Clinical Practice, vol. 154, pp. 116-123.

Leoutsakos, J. M., Muthen, B. O., Breitner, J. C., Lyketsos, C. G., & ADAPT Research Team (2012). Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial.", International journal of geriatric psychiatry, vol. 27, no. 4, pp. 364–374.

Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns,

A., Cohen-Mansfield, J., Cooper, C., Costafreda, S.G., Dias, A., Fox, N., Gitlin, L.N., Howard, R.,

654	Kales, H.C., Kivimaki, M., Larson, E.B., Ogunniyi, A., Orgeta, V., Ritchie, K., Rockwood, K.,
655	Sampson, E.L., Samus, Q., Schneider, L.S., Selbaek, G., Teri, L. & Mukadam, N. 2020, "Dementia
656	prevention, intervention, and care: 2020 report of the Lancet Commission", Lancet, vol. 396,
657	no. 10248, pp. 413-446.

- McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. & Stadlan, E.M. 1984, "Clinical
- 659 diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the

auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.",

661 Neurology, vol. 34, no. 7, pp. 939-944.

660

McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R.J., Kawas, C.H., Klunk,

W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., Morris, J.C., Rossor, M.N.,
Scheltens, P., Carrillo, M.C., Thies, B., Weintraub, S. & Phelps, C.H. 2011, "The diagnosis of
dementia due to Alzheimer's disease: recommendations from the National Institute on AgingAlzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.",
Alzheimer's & Dementia, vol. 7, no. 3, pp. 263-269.

- Moore, E.M., Mander, A.G., Ames, D., Kotowicz, M.A., Carne, R.P., Brodaty, H., Woodward,
- 669 M., Boundy, K., Ellis, K.A., Bush, A.I., Faux, N.G., Martins, R., Szoeke, C., Rowe, C., Watters,
- D.A. & AIBL Investigators 2013, "Increased risk of cognitive impairment in patients with
- diabetes is associated with metformin.", Diabetes care, vol. 36, no. 10, pp. 2981-2987.
- 672 Morris, J.C. 1993, "The Clinical Dementia Rating (CDR): Current version and scoring rules",
- 673 Neurology, vol. 43, no. 11, pp. 2412-2414.
- Morris, J.C., Weintraub, S., Chui, H.C., Cummings, J., Decarli, C., Ferris, S., Foster, N.L., Galasko,
- D., Graff-Radford, N., Peskind, E.R., Beekly, D., Ramos, E.M. & Kukull, W.A. 2006, "The Uniform

- Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease
- 677 Centers.", Alzheimer Disease & Associated Disorders, vol. 20, no. 4, pp. 210-216.
- 678 Newcombe, E.A., Camats-Perna, J., Silva, M.L., Valmas, N., Huat, T.J. & Medeiros, R. 2018,
- ⁶⁷⁹ "Inflammation: the link between comorbidities, genetics, and Alzheimer's disease", Journal of
- 680 Neuroinflammation, vol. 15, no. 1, pp. 276.
- Nikaido A.M., Ellinwood Jr. E.H., Heatherly D.G. & Gupta, S.K. 1990, "Age-related increase in
- 682 CNS sensitivity to benzodiazepines as assessed by task difficulty.", Psychopharmacology, vol.
- 683 100, no. 1, pp. 90-97.
- Nishtala P.S., Salahudeen M.S. & Hilmer, S.N. 2016, "Anticholinergics: theoretical and clinical
- overview.", Expert Opinion on Drug Safety, vol. 15, no. 6, pp. 753-768.
- 686 Obermann K.R., Morris J.C. & Roe, C.M. 2013, "Exploration of 100 commonly used drugs and
- supplements on cognition in older adults.", Alzheimer's and Dementia, vol. 9, no. 6, pp. 724-732.
- 689 O'Bryant S.E., Lacritz L.H., Hall J., Waring S.C., Chan W., Khodr Z.G., Massman P.J., Hobson V.
- 690 & Cullum, C.M. 2010, "Validation of the new interpretive guidelines for the clinical dementia
- rating scale sum of boxes score in the National Alzheimer's Coordinating Center database.",
- 692 Archives of Neurology, vol. 67, no. 6, pp. 746-749.
- 693 Ou, Y., Tan, C., Shen, X., Xu, W., Hou, X., Dong, Q., Tan, L. & Yu, J. 2020, "Blood Pressure and
- 694 Risks of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of 209
- 695 Prospective Studies", Hypertension, vol. 76, no. 1, pp. 217-225.

Peters, R., Booth, A., Rockwood, K., Peters, J., D'Este, C. & Anstey, K.J. 2019, "Combining
modifiable risk factors and risk of dementia: a systematic review and meta-analysis.", BMJ
Open, vol. 9, no. 1, pp. e022846.

Petersen R.C. & Morris, J.C. 2005, "Mild cognitive impairment as a clinical entity and
treatment target.", Archives of Neurology, vol. 62, no. 7, pp. 1160-1163.

Raj, D., Yin, Z., Breur, M., Doorduin, J., Holtman, I.R., Olah, M., Mantingh-Otter, I.J., Van Dam,

D., De Deyn, P.P., den Dunnen, W., Eggen, B.J.L., Amor, S. & Boddeke, E. 2017, "Increased

703 White Matter Inflammation in Aging- and Alzheimer's Disease Brain.", Frontiers in Molecular

Neuroscience, vol. 10, pp. 206.

Ravona-Springer, R., Heymann, A., Schmeidler, J., Moshier, E., Godbold, J., Sano, M., Leroith,

D., Johnson, S., Preiss, R., Koifman, K., Hoffman, H., Silverman, J.M. & Beeri, M.S. 2014, "Trajectories in glycemic control over time are associated with cognitive performance in elderly subjects with type 2 diabetes.", PLoS ONE [Electronic Resource], vol. 9, no. 6, pp. e97384.

Rouch, L., Cestac, P., Hanon, O., Cool, C., Helmer, C., Bouhanick, B., Chamontin, B., Dartigues,
J., Vellas, B. & Andrieu, S. 2015, "Antihypertensive drugs, prevention of cognitive decline and
dementia: a systematic review of observational studies, randomized controlled trials and
meta-analyses, with discussion of potential mechanisms.", CNS Drugs, vol. 29, no. 2, pp. 113130.

Salahudeen M.S., Duffull S.B. & Nishtala, P.S. 2015, "Anticholinergic burden quantified by
anticholinergic risk scales and adverse outcomes in older people: a systematic review.", BMC
geriatrics, vol. 15, pp. 31.

Salzman, C. 2020, "Do Benzodiazepines Cause Alzheimer's Disease?.", American Journal of
Psychiatry, vol. 177, no. 6, pp. 476-478.

720 Schneider, L.S., Insel, P.S., Weiner, M.W. & for the Alzheimer's Disease Neuroimaging

721 Initiative 2011, "Treatment With Cholinesterase Inhibitors and Memantine of Patients in the

Alzheimer's Disease Neuroimaging Initiative", Archives of Neurology, vol. 68, no. 1, pp. 58-66.

Shah, K., Qureshi, S.U., Johnson, M., Parikh, N., Schulz, P.E. & Kunik, M.E. 2009, "Does use of
antihypertensive drugs affect the incidence or progression of dementia? A systematic
review.", American Journal of Geriatric Pharmacotherapy, vol. 7, no. 5, pp. 250-261.

Trenaman, S.C., Rideout, M. & Andrew, M.K. 2019, "Sex and gender differences in
polypharmacy in persons with dementia: A scoping review.", SAGE Open Medicine, vol. 7, pp.
2050312119845715.

Verdoux, H., Lagnaoui, R. & Begaud, B. 2005, "Is benzodiazepine use a risk factor for cognitive
decline and dementia? A literature review of epidemiological studies.", Psychological
medicine, vol. 35, no. 3, pp. 307-315.

Wancata, J., Borjesson-Hanson, A., Ostling, S., Sjogren, K. & Skoog, I. 2007, "Diagnostic criteria
influence dementia prevalence.", American Journal of Geriatric Psychiatry, vol. 15, no. 12, pp.
1034-1045.

Wu C.Y., Ouk M., Wong Y.Y., Anita N.Z., Edwards J.D., Yang P., Shah B.R., Herrmann N., Lanctot
K.L., Kapral M.K., MacIntosh B.J., Rabin J.S., Black S.E. & Swardfager, W. 2020, "Relationships
between memory decline and the use of metformin or DPP4 inhibitors in people with type 2
diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status.",
Alzheimer's and Dementia, vol. 16, no. 12, pp. 1663-1673.

740	Yasar, Sevil Xia, Jin Yao, Wenliang Furberg, Curt D., Xue, Q.M., Carla I., Fitzpatrick, A.L., Fried,
741	L.P., Kawas, C.H., Sink, K.M., Williamson, J.D., DeKosky, S.T., Carlson, M.C. & For the Ginkgo
742	Evaluation of Memory Study Investigators 2013, "Antihypertensive drugs decrease risk of
743	Alzheimer disease: Ginkgo Evaluation of Memory Study", Neurology, vol. 81, no. 10, pp. 896-
744	903.

- Yeung, A., Kiss, A. & Gallagher, D. 2020, "Intensive control of hypertension and risk of Alzheimer's dementia in older adults with depression.", International journal of geriatric psychiatry, vol. 35, no. 8, pp. 888-896.
- Zammitt, N.N.M. & Frier, B.M. 2005, "Hypoglycemia in Type 2 Diabetes: Pathophysiology,
- frequency, and effects of different treatment modalities", Diabetes care, vol. 28, no. 12, pp.
 2948-2961.
- Zhang, C., Wang, Y., Wang, D., Zhang, J. & Zhang, F. 2018, "NSAID Exposure and Risk of
 Alzheimer's Disease: An Updated Meta-Analysis From Cohort Studies.", Frontiers in aging
 neuroscience, vol. 10, pp. 83.